GNI Group Ltd.
2160・Growth Market・Pharmaceuticals
Governance
The company has adopted the company-with-committees governance structure, with a board of directors comprising 7 members (including 3 outside directors). Business execution and oversight functions are separated, and three committees—nomination, compensation, and audit—have been established. The board of directors met 27 times during the fiscal year under review.
Risk Management
No standing risk management committee is established; the Board of Directors and each committee (Audit, Compensation, Nomination) directly oversees risks within their respective areas of responsibility. The Board receives regular risk reports from the CEO and other members of management, and strategic risks are evaluated directly by the Board of Directors.
Shareholder Returns
No dividends for both FY2025 (ending December 2025) and FY2026 (ending December 2026) (annual dividend of ¥0). No change to dividend forecast. No share buyback has been confirmed.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0. The forecast for FY2026 (ending December 2026) is also an annual dividend of ¥0 (only a year-end dividend is set, with no interim dividend). There has been no revision from the most recently announced dividend forecast.
ESG
The company positions addressing unmet medical needs as the foundation of its business, promoting workforce diversity (women accounted for 64% of unconsolidated employees in 2025), reduction of environmental impact, and climate change response. Specific numerical targets have not been set, with details disclosed in the annual ESG report.
Last updated: March 27, 2026